Articles tagged with: Lenalidomide
NewsFlash »
Bafetinib May Prevent Bone Loss For Cancer Patients – A series of preclinical studies indicate that the drug bafetinib (INNO-406) inhibits bone deterioration in cancer patients who are at high risk for bone loss, including multiple myeloma patients. Although bafetinib is being developed by CytRX for the treatment of certain types of leukemia, the latest preclinical studies showed that bafetinib also suppresses the activity of bone cells that break down bone and cause fractures, bone pain, and high blood calcium levels. Bafetinib is also being tested in ongoing clinical trials for effectiveness against prostate cancer and brain tumors. For more information, please see the CytRx Corporation press release.
Phase 2 Study Will Examine Curcumin’s Ability To Reduce Myeloma Symptoms During Maintenance Therapy – M.D. Anderson Cancer Center in Houston will begin a Phase 2 clinical trial to determine whether curcumin, the active ingredient in the Indian spice turmeric, can reduce symptoms of myeloma for patients taking Revlimid (lenalidomide) as maintenance therapy. Researchers will assess the effects of curcumin on pain, fatigue, bone aches, numbness, and disturbed sleep. The trial, which is not yet enrolling patients, will begin in June and include approximately 70 participants. For more information, please see the United States Clinical Trials Registry.
MMRF Patient Symposium To Be Held In Los Angeles – The Multiple Myeloma Research Foundation (MMRF) will hold a symposium for myeloma patients and their families on February 26 at Intercontinental Los Angeles Century City. After a basic introduction to multiple myeloma, leading myeloma experts will speak about managing bone disease, treatment options for myeloma patients, and clinical trials. A panel of myeloma experts will also be available to answer questions from patients and family members. Registration will begin at 8:30 a.m., and the program will conclude at 2:30 p.m. For more information or to register, please visit the MMRF website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News»
A split may be developing in the multiple myeloma research community regarding the treatment implications of a possible link between long-term Revlimid use and secondary cancers.
Many researchers are going on record saying the current controversy does not justify any change in the use of Revlimid (lenalidomide) as a myeloma therapy. Other researchers, however, believe the controversy raises important questions that justify more cautious use of the drug.
Concerns about a potential Revlimid-secondary cancer link first emerged at the American Hematology Society annual meeting in December. At the meeting, results were …
News»
The Myeloma Beacon has learned that the Cancer and Leukemia Group B, the cooperative group running the CALGB / ECOG / BMT-CTN 100104 Revlimid maintenance trial, currently has no plans to halt Revlimid therapy in its trial.
The CALGB trial is one of three trials which released data last December that raised concerns about a potential link between long-term Revlimid (lenalidomide) use and second cases of cancer in multiple myeloma patients.
Among the 231 patients in the Revlimid maintenance arm of the CALGB trial, 15 second cancers have been reported. Among …
News»
Several investment bank reports published this week have heightened concern about a potential link between Revlimid and second cancers in multiple myeloma patients. The reports have unnerved investors to such a degree that the stock of Celgene, Revlimid’s manufacturer, is down almost nine percent since the middle of last week.
Apprehension about Revlimid (lenalidomide) and secondary cancer first surfaced in December during the American Society of Hematology (ASH) annual meeting. At the meeting, results were presented from three trials studying long-term Revlimid use. All three trials showed more cases of …
News»
New information was released last week regarding long-term treatment with Revlimid and a multiple myeloma patient’s risk of developing a second cancer.
The information is based on analyses prompted by results from three clinical trials presented at the American Society of Hematology meeting last month. In each of the three trials, more multiple myeloma patients receiving Revlimid maintenance therapy reported developing a secondary cancer than patients who did not receive maintenance therapy.
Celgene, the manufacturer of Revlimid (lenalidomide), announced the results of the follow-up analyses during a quarterly earnings conference …
News»
Results of a recent Canadian study show that the use of novel agents, particularly Velcade and Revlimid, as salvage therapy after stem cell transplantation improves overall survival and post-relapse survival of multiple myeloma patients, including high-risk patients who relapsed early following transplantation.
Although multiple myeloma remains an incurable disease, the introduction of novel agents, such as thalidomide (Thalomid), Velcade (bortezomib), and Revlimid (lenalidomide) has lead to significant improvements in disease outcomes.
In their analysis, the Canadian researchers sought to determine the effect of these novel agents on the outcomes …
News»
Multiple myeloma patients who continued Revlimid treatment after achieving at least a partial response experienced significantly higher overall survival compared to patients who discontinued treatment, according to a recent study published in the journal Clinical Lymphoma, Myeloma, & Leukemia.
However, the study authors noted that proper management of side effects is necessary for patients to achieve the survival benefit.
Two previous Phase 3 trials showed that Revlimid (lenalidomide) plus dexamethasone (Decadron) improved overall survival more than dexamethasone alone in patients with relapsed or refractory (resistant) myeloma (38.0 months versus …
